• Profile
Close

Pregnancy outcomes of female childhood cancer survivors: A nationwide survey in Japan

Pediatrics International Jan 07, 2018

Sekiguchi M, et al. - This trial incorporated an inspection of the outcomes of pregnancies among female childhood cancer survivors (CCSs) in Japan. The intention was to encourage greater attention to the reproductive health of CCSs. Findings revealed a small number of deliveries of CCSs in Japan. However, the pregnancy outcomes were favorable. Significant aspects for the management of pregnancies in CCSs were preterm delivery due to obstetrical complications, especially in CCSs with radiotherapy, and epilepsy serving as the maternal complications that were suspected to be associated with previously received treatments.

Methods

  • The scheme of this research was a retrospective nationwide survey.
  • It was carried out using a questionnaire on deliveries at ≥22 weeks of gestation in CCSs at perinatal centers registered with the Japanese Perinatologists Association between 2010 and 2014.
  • Herein, a scrutiny was conducted of the maternal characteristics, pregnancy and neonatal outcomes and the connection between cancer treatments and these outcomes.

Results

  • Data revealed that the total number of CCSs was 61, and the total number of deliveries was 71, corresponding to 0.019% of total deliveries.
  • Leukemia was reported in 46% of the cases, with regard to cancer.
  • Seven cases (11%) presented with epilepsy.
  • As per the results, the mean gestational age at delivery was 37.9 weeks.
  • The rate of preterm delivery was 24%.
  • The mean birth weight was disclosed to be 2,718 g.
  • A total of 3 congenital anomalies (4.2%) were found.
  • Findings illustrated higher rate of preterm delivery and the mean birth weight appeared to be lighter in women treated with radiotherapy than in those without radiotherapy (42% vs. 16%, P=0.025; 2,436 ± 737 g vs. 2,827 ± 483 g, P=0.010).
  • Researchers determined that the adjusted odds ratio of radiotherapy for preterm deliveries was 3.53 (P=0.049).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay